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Inhibitionof autophagy inEBV-positiveBurkitt’s lymphoma
cells enhances EBV lytic genes expression and replication
A De Leo1,5,6,7, F Colavita1,6,8, F Ciccosanti2, GM Fimia2,3, PM Lieberman4 and E Mattia*,1
Autophagy, an important degradation system involved in maintaining cellular homeostasis, serves also to eliminate pathogens and
process their fragments for presentation to the immune system. Several viruses have been shown to interact with the host
autophagic machinery to suppress or make use of this cellular catabolic pathway to enhance their survival and replication. Epstein
Barr virus (EBV) is a γ-herpes virus associated with a number of malignancies of epithelial and lymphoid origin in which
establishes a predominantly latent infection. Latent EBV can periodically reactivate to produce infectious particles that allow the
virus to spread and can lead to the death of the infected cell. In this study, we analyzed the relationship between autophagy and
EBV reactivation in Burkitt’s lymphoma cells. By monitoring autophagy markers and EBV lytic genes expression, we demonstrate
that autophagy is enhanced in the early phases of EBV lytic activation but decreases thereafter concomitantly with increased levels
of EBV lytic proteins. In a cell line defective for late antigens expression, we found an inverse correlation between EBV early
antigens expression and autophagosomes formation, suggesting that early after activation, the virus is able to suppress
autophagy. We report here for the first time that inhibition of autophagy by Bafilomycin A1 or shRNA knockdown of Beclin1 gene,
highly incremented EBV lytic genes expression as well as intracellular viral DNA and viral progeny yield. Taken together, these
findings indicate that EBVactivation induces the autophagic response, which is soon inhibited by the expression of EBV early lytic
products. Moreover, our findings open the possibility that pharmacological inhibitors of autophagy may be used to enhance
oncolytic viral therapy of EBV-related lymphomas.
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Epstein Barr Virus (EBV) causes infectious mononucleosis
and it is associated with several tumors of both epithelial and
B-cell origin such as Burkitt’s lymphoma (BL), nasopharyngeal
carcinoma, Hodgkin’s disease and lymphoproliferative dis-
orders occurring in post-transplant patients and human
immunodeficiency virus (HIV)-infected individuals. Alike all
herpes viruses, EBV has both a latent and a lytic replication
program. Besides the oncogenic potential of several EBV
latent genes, lytic products may also be relevant for the
development of EBV-associated malignancies.1 EBV produc-
tive infection, allowing the virus to spread, increases the pool
of latently infected cells increasing the risk of a clonal
expansion of EBV-positive B lymphocytes in immunocompro-
mised individuals. Mechanisms regulating the switch from
latent to lytic infection may enable new strategies for treating
EBV-associated cancers, referred to as oncolytic therapy.2,3
Physiological stimuli that trigger viral reactivation in vivo have
not been clearly identified. However, in vitro, viral reactivation
can be achieved by treating EBV latently infected cells
with different chemical or biological inducers, such as
12-O-tetradecanoylphorbol-13-acetate, calcium ionophore,
histone deacetylase (HDAC) inhibitor, anti-immunoglobulin
G (anti-IgG, IgG) or transforming growth factor beta (TGFβ).4
During the lytic cycle, the sequential expression of immediate
early, early and late genes leads to viral particles production.
The two immediate early products, BZLF1 and BRLF1,
promote each other expression, transactivate separate
classes of EBV lytic genes and together synergize to activate
a third class of lytic genes.
Several studies indicate that autophagy has a role in
pathogen infection. Autophagy is a complex degradation
process by which cytoplasmic material, including soluble
macromolecules and organelles, is delivered to lysosomes.
Autophagy-related genes (ATG) have been identified in yeast,
and many of them have orthologs in mammalian cells.5 These
genes control a multistep mechanism leading to the formation
of the autophagosome, a double-membrane vesicle, which, by
fusing with lysosomes, forms the autolysosomes where the
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delivered contents are ultimately degraded. Under normal
conditions, the serine/threonine kinase mammalian target of
rapamycin (mTOR) phosphorylates Ulk-like kinase 1 and 2,
thus repressing autophagy induction.6 Conditions such as
starvation, metabolic stress, response to some microbial
infection or treatment with mTOR inhibitor rapamycin impede
mTOR kinase activity, thus activating autophagy. Initially,
Beclin1 (BECN1), which constitutively binds cellular Bcl2,
forms a complex with Vps34, a phosphatidylinositol 3-kinase
(PI3K), which participates in autophagosome nucleation.7
During the elongation step of autophagy, microtubule-
associated protein light chain 3-I (LC3-I) is processed and
conjugated with phosphatidylethanolamine as LC3-II form.
Lipidated LC3-II associates with autophagosomal membrane
and therefore serves as a marker for autophagosome
formation.8
Autophagy can function as an antimicrobial defense by
contributing to degrade intracellular microorganisms, and to
regulate innate and adaptive immunity against viral infections.
Some viruses, such as herpes simplex virus type 1 (HSV1),
human cytomegalovirus (HCMV), Kaposi’s sarcoma-
associated herpesvirus (KSHV) and HIV have evolved
molecular mechanisms to successfully evade autophagy.9–13
Moreover, other viruses such as coxsackie virus, dengue
virus, influenza A virus, hepatitis C virus, varicella-zoster virus
and BK polyomavirus induce and profit from autophagy to
promote their own replication.14–19
In this study, we investigated the role of autophagy during
EBV productive infection in cellular models allowing the
complete or partial expression of the viral genome. We
evaluated the expression of key autophagy proteins and the
formation of autophagic vesicles in BL cells exposed to
physiologically relevant EBV activating compounds such as
anti-IgG and TGFβ or to chemical inducers. Moreover, by
altering the pathway with autophagy modulators and shRNA-
based suppression of Beclin1 expression, we found that
inhibition of autophagy in the early as well as in the late phase
of the process, largely promotes EBV transcription and
replication. We suggest that the host cell enhances autophagy
as a response to viral reactivation, but early in the lytic cycle of
infection, EBV is able to counteract autophagy.
Results
Induction of EBV lytic cycle transiently activates autophagy.
In isogenic EBV-negative and EBV-positive Akata cells
exposed to anti-IgG and Mutu-I cells treated or not with
TGFβ, we measured the levels of three autophagy marker
proteins. By immunoblot analysis, we examined the expres-
sion of LC3-II that correlates with the formation of the
autophagosomes; ATG12/ATG5 as autophagy conjugation
system and Beclin1 involved in the early steps of the
autophagy pathway. Figure 1a shows that LC3-I and LC3-II
components were more abundant in the cells not infected by
EBV. LC3-II levels in EBV-negative Akata cells markedly
increased during the first 8-h exposure to IgG but decreased
thereafter. Treatment of EBV-positive Akata cells with IgG for
the same lengths of time induced the expression of BZLF1
and BRLF1 indicating the extent of EBV lytic cycle activation.
LC3-II modulation in these cells showed a trend similar to that
observed in EBV-negative Akata cells. However, the relative
increment of LC3-II between 6 and 8 h, and the following
reduction between 8 and 24 h were higher (2.3- and 4.3-fold)
in the EBV-positive as compared with the EBV-negative cells
(1.9- and 3-fold). Moreover, in the samples of EBV-positive
Akata cells collected at 24 h, LC3-II was 30% less than
the amount measured at time zero. In contrast, in the
EBV-negative cells, at 24 h LC3-II, signal was ~ 50% higher
than that measured at time zero. Neither ATG12/ATG5
complex nor Beclin1 levels changed significantly in EBV-
positive and EBV-negative cells. Figure 1b shows the results
obtained from Mutu-I cells untreated or exposed to TGFβ to
induce EBV lytic cycle. EBV lytic transactivators BZLF1 and
BRLF1 were more strongly detected in these cells after 24 h
exposure to TGFβ. About a twofold increment of LC3-II
occurred during the first 4 h of incubation followed by a drastic
decrement. In the 24- and 48-h samples, LC3-II content was
~50% of that detected at time zero. Smaller variations were
measured in the levels of ATG12/ATG5 complex and Beclin1,
with a pattern similar to that of LC3-II. Changes in the marker
levels also occurred in untreated Mutu-I cells incubated under
the same conditions used for EBV activation by TGFβ.
To confirm autophagic flux with EBVactivation, the levels of
LC3-II were determined following treatment with or without
Bafilomycin A1, an inhibitor of lysosomal degradation.
As shown in Figure 2a, addition of IgG activates autophagy
both in EBV-negative and EBV-positive Akata cells. However,
as compared with the uninfected ones, EBV-positive Akata
cells showed a substantial increment of LC3-II after 8 h
incubation with the inhibitor. In addition, independently of the
treatment with Bafilomycin A, similar levels of LC3-II were
detected in the samples collected at 24 h, suggesting inhibition
of the autophagic flux. These results indicated that the
increment of the LC3-II component in EBV-positive Akata
cells depended not only on the cellular response to IgG
exposure but also to a transient stimulation of autophagy that
correlated with EBV reactivation. Similarly, Mutu-I cells were
incubated with TGFβ in the absence and presence of
Bafilomycin A1. The bar graph of Figure 2b clearly indicates
an increment of the autophagic flux in the first 4 h of incubation
while no differences were measured at later time points,
thereby suggesting an arrest of the autophagic flux also in this
cell line along with EBV reactivation.
Modulation of autophagy activity affects EBV lytic
antigens expression. To explore the relationship between
autophagy and EBV lytic infection, the virus productive cycle
was induced in Akata and Mutu-I cells in the absence or in
the presence of pharmacological agents that either inhibit or
stimulate the autophagic pathway. Bafilomycin A1, a vacuolar
ATPase inhibitor that blocks lysosomal acidification as well as
the fusion of autophagosomes with the lysosomes, and
Rapamycin, a drug that inhibits mTOR, were used to inhibit or
to enhance autophagy, respectively. Cell samples collected at
8 and 24 h were analyzed by immunoblot for the expression
of EBV lytic antigens BZLF1, BRLF1 and the early DNA
polymerase BALF5. The activity of the two autophagy
modulators was verified by detecting the increment of LC3-
II with Bafilomycin A1 and the reduced phosphorylation of the
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TORC1 substrate p70S6 with Rapamycin (data not shown).
Figure 3a shows that exposure of Akata and Mutu-I cells to
EBV activators in the presence of Bafilomycin A1 strongly
increased lytic antigens expression. In contrast, Rapamycin
slightly affected viral protein levels in both cell lines,
suggesting that the increment of autophagy by EBVactivation
does not involve mTOR signaling.
It was reported that EBV immediate early protein Rta
activates autophagy by upregulating ERK activity.20 We
investigated the role of ERK signaling pathway in Akata and
Mutu-I cells exposed to EBVactivators with or without theMEK
inhibitor U0126 for 24 h. Western blot analysis of phosphory-
lated ERK1/2, LC3-II and BZLF1 levels revealed that the
expression of EBV lytic antigens activated ERK pathway, and
that ERK phosphorylation was inhibited by U0126
(Supplementary Figure 1). Moreover, U0126 diminished the
amount of LC3-II while delayed and markedly reduced the
expression of BZLF1, indicating that ERK signaling affects
both autophagy as well as the EBV lytic antigen expression.
We next detected the subcellular distribution of EBV early
antigens (EA) and autophagosomes upon lytic cycle induction
with or without Bafilomycin A1. For this purpose, we used
latently infected Raji cells that, when treated with P(BU)2,
sodium butyrate and TGFβ, allow EBV reactivation while
undergoing morphological changes, which promote adhesion
to the glass. Under these conditions, we visualized endogen-
ous LC3 puncta corresponding to autophagosomes and EBV
lytic proteins with antibodies specific for LC3 and for EBV EA.
Figure 1 Expression of autophagy marker proteins in EBV-infected BL cells. (a) EBV-negative and EBV-positive Akata cells were treated with IgG as described in the
Materials and Methods section. Cell extracts from samples collected at the indicated times were analyzed by immunoblotting using antibodies against BRLF1, BZLF1, LC3,
ATG12/ATG5, BECN1 and β-actin as loading control. (b) Mutu-I cells untreated or treated with TGFβ were analyzed as in a. The relative levels of the targeted proteins were
obtained by densitometric analysis of the ratio of the specific signals to β-actin. The data represent the mean±S.D. of three independent experiments
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As illustrated in the upper panels of Figure 3b, after 24 h
incubation, fluorescence signals enlightened LC3 puncta in
the cytoplasm and EBV EA in the nucleus of ~ 40% of the cell
population.21 Surprisingly, as shown in the merge of the two
images and in the magnified insert, cells that did stain for EBV
EA did not stain for LC3 and vice versa, indicating that EBV EA
expression blocked autophagy. Addition of Bafilomycin A1
during EBV lytic cycle induction increased the number of LC3
puncta per cell and augmented by ~2-fold, the number of
EA-positive cells (Figure 3b, lower panels), confirming the
increment of lytic antigens expression observed by immuno-
blot analysis.
Bafilomycin A1 increases EBV EA transcription and
EBV replication. To elucidate whether the Bafilomycin
A1-mediated increment of EBV EA was regulated at the
transcriptional level, we measured, by quantitative RT-PCR,
the transcripts of BALF5, the catalytic component of the viral
DNA polymerase, BMRF1, the polymerase accessory
protein, and BHLF1, the essential OriLyt promoter.22 As
shown in Figure 4, exposure of both Akata and Mutu-I cells to
Bafilomycin A1 during EBV activation significantly increased
EBV lytic gene transcription. The extent of the upregulation of
the three EBV transcripts, ranging from ~2.5- to 15-fold, was
different in the two cell lines, likely reflecting the different time
course of EBV lytic gene expression.
To assess whether the enhancement of EBV lytic antigens
transcription correlated with increased EBV replication, we
determined by real-time PCR that intracellular viral DNA as
well as the viral progeny yield released in the medium.
Figure 5a shows that intracellular viral DNA copies in Akata
cells exposed for 24 h to IgG with Bafilomycin A1 were about
twice asmany as thosemeasured without. Similarly, treatment
of Mutu-I cells with TGFβ plus Bafilomycin A1 for 48 h
increased EBV DNA copies by ~30%. In addition, the results
illustrated in Figure 5b show that EBV particles detected in the
culture medium of Akata and Mutu-I cells, exposed to EBV
activators plus Bafilomycin A1, were about twice as abundant
as those found in the medium of control cells. Moreover, in
agreement with the results obtained by western blot analysis,
in both cell lines, Rapamycin only slightly reduced intracellular
EBV DNA copies and released viral particles as compared
with the values determined in the cells exposed to IgG or to
TGFβ alone (Figures 5a and b).
Knockdown of endogenous Beclin1 increases EBV
transcription and replication. To further elucidate the
effects of restricting autophagy on EBV lytic infection, shRNA
molecular silencing was used to suppress the expression of
Beclin1, an essential protein involved in the early steps of the
autophagic process. Figure 6a shows that Beclin1-silenced
Akata cells exhibited very low levels of the protein as
compared with control cells transfected with scrambled
shRNA sequences. Notably, upon EBV activation, Beclin1-
silenced Akata showed a strong increment in the levels of
EBV lytic antigens BZLF1, BRLF1 and BALF5, as compared
with control cells. RT-PCR experiments revealed that Beclin1
inhibition enhanced the transcription of EBV lytic genes
(data not shown). Moreover, as illustrated in Figure 6b,
Beclin1 knockdown in the cells exposed to IgG for 24 h,
increased viral DNA replication by ~ 3-fold and the viral
progeny yield by ~2-fold.
Similarly, Beclin1 knockdown in Mutu-I cells determined a
significant increment of EBV lytic antigens, intracellular viral
DNA and viral particles released in the medium
(Supplementary Figure 2).
All together, these results clearly indicate that impairment of
the autophagic pathway, also at an early step of the process,
highly improves EBV gene expression and replication.
Discussion
Viruses have been found to increase or block autophagy to
enhance their replication. On the other side, several studies
indicate that autophagy is activated upon viral infection to
Figure 2 LC3-II turnover assay. EBV- positive and EBV-negative Akata cells (a) and Mutu-I cells (b) were treated with IgG or TGFβ, respectively, in the absence or in the
presence of Bafilomycin A1 (BafA1) as described in the Materials and Methods section. At the indicated times, samples were subjected to immunoblot analysis with LC3
antibodies. The bar graph in a illustrates the densitometric measurements of the LC3-II signals normalized to β-actin. The values of the bar graph in b represent the ratio between
the densitometric measurements of the LC3-II signals detected in the presence and in the absence of BafA1, normalized to β-actin. The data represent the mean± S.D. of three
independent experiments
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hamper viral replication and thereby protect the cells. In
general, herpes viruses after an initial stimulation are able to
block the autophagic process. HSV1 and HCMV cause an
early induction of autophagy in human fibroblasts.23 However,
at later times during infection, ICP34.5 and TRS1 proteins
produced by HSV1 and HCMV, respectively, actively counter-
act autophagosome biogenesis by binding and inhibiting
Beclin1.9,11 In KSHV, the replication and transcription activator
RTA is able to enhance autophagy.24 Nevertheless, KSHV
proteins K7, vBcl2 and vFLIP inhibit various steps of the
autophagic pathway.12,25,26
In this study, we examined the role of autophagy upon EBV
activation in three BL cell lines, two of them allowing the virus
to execute the complete lytic program and one that contains a
defective EBV genome expressing only the immediate early
and the early genes. By treating Akata and Mutu-I cells with
IgG and TGFβ, compounds that mimic physiologically relevant
mechanisms triggering the transition from latent to lytic
infection,27 we found the autophagosomal marker LC3-II to
increase at the early times, but decrease thereafter, in
correlation with a larger expression of EBV early lytic genes.
We also observed an increment of LC3-II levels in EBV-
Figure 3 Effects of autophagy modulators on EBV lytic antigen expression. (a) EBV lytic cycle was induced in Akata and Mutu-I cells with IgG and TGFβ, respectively, in the
absence or in the presence of either Bafilomycin A1 or Rapamycin. Lysates obtained from the cell samples collected at the indicated times were subjected to immunoblot analysis
using antibodies against BRLF1, BZLF1 and BALF5. β-Actin was used as loading control. A representative experiment out of three is shown. The relative levels of the targeted
proteins were estimated by densitometry and the ratios were calculated relative to β-actin. The data represent the mean± S.D. of three independent experiments. (b) Raji cells
treated with EBV inducing agents for 48 h in the absence or in the presence of Bafilomycin A1 were fixed and stained with anti-LC3 and anti-EA antibodies, followed by the
corresponding secondary antibodies conjugated to TRITC and FITC, respectively, as described in the Materials and Methods section. The magnified image corresponds to the
white-square frame-enclosed region enlightened in the merge image. Scale bar, 20 μm. The bar graph illustrates the data as the percentages of EA-positive cells in the absence
or in the presence of Bafilomycin A1. The data represent the mean±S.D. of three similar experiments
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negative Akata cells exposed to IgG and in untreated Mutu-I
cells during the first 8-h incubation. These data indicate in one
case that IgG cross-linking, per se, activates autophagy, and in
the other case that the autophagic machinery is extremely
sensitive and might be perturbed by the experimental
procedures (centrifugation and concentration) the cells are
subjected to. However, the larger reduction of LC3-II in the
EBV-infected Akata and inMutu-I cells exposed to TGFβ for 24
or 48 h strongly suggests that EBV lytic antigens expression
more effectively contributes to downregulate autophagy.
Interestingly, the levels of the autophagic proteins on the
average were higher in the uninfected than in the infected
Akata cells, possibly indicating a lower basal autophagic
activity in the cells harboring the virus. Measurements of the
autophagic flux by LC3-II turnover revealed that increased
LC3-II levels were due to an increment in the autophagic
activity rather than to a block in downstream factors affecting
LC3-II turnover, and that this increment occurred at the early
Figure 4 Effects of autophagy inhibition on EBV lytic transcripts. EBV lytic cycle was induced in Akata and Mutu-I cells in the absence or in the presence of Bafilomycin A1.
After 24 h, samples were collected and RNA extracted. After retro-transcription, the cDNA was analyzed by real-time PCR with specific primers for BHLF1, BALF5 and BMRF1,
and the values were normalized for GAPDH. Fold changes in gene expression levels upon EBV lytic cycle induction were calculated by comparison of the gene expression in
Bafilomycin A1-treated cells with the untreated ones, which were assigned an arbitrary value of 1. All reactions were performed in triplicate. ∗Po0.05, ∗∗Po0.01 and
∗∗∗Po0.001
Figure 5 Inhibition of autophagy by Bafilomycin A1 enhances EBV replication. Akata were exposed to IgG for 24 h and Mutu-I cells to TGFβ for 48 h in the absence or in the
presence of Bafilomycin A1 or Rapamycin. Intracellular (a) and extracellular (b) EBV DNA copies were detected by real-time PCR as described in the Materials and Methods
section. The data representing the mean±S.D. of three independent experiments are expressed as fold increment of the treated versus untreated (con) cells. ∗Po0.05 and
∗∗Po0.01
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times of EBV activation. Moreover, ERK signaling pathway
was involved in upregulating autophagy as well as BZLF1
expression.
It was recently reported that EBV immediate early product
Rta induces autophagy, and that ATG5 mediates the Rta-
induced autophagic activity in transfected 293 T cells.20 We
did not detect significant variations in the levels of either ATG
5/12 complex or Beclin1 in our EBV reactivation models. It is
possible that the full expression of EBV lytic antigens in Akata
and Mutu-I allows one or more viral products to effectively
counteract the cellular autophagic response. Strikingly in Raji
cells that host a deleted EBV genome, we discovered an
inverse relationship between EBV EA expression and
autophagosomes formation. Because in these cells EBV late
antigens are not expressed, it is conceivable to find within the
set of EBV EA the effectors of autophagy suppression.
Wortmannin and 3-MA are pharmacological autophagy
inhibitors used to block the formation of autophagosomes.
However, both compounds are inhibitors of PI3K, the principal
mediator of EBV reactivation induced by BCR signaling.28,29
Moreover, PI3K activation is required for Rta-induced activa-
tion of BZLF1 and the early gene BMRF1.30 Therefore, to
avoid compounds that might affect EBV reactivation, we used
Bafilomycin A1 and shRNA-based depletion of Beclin1, an
essential protein for autophagy initiation to block, respectively,
a late and an early step of the degradation pathway. We show
here that induction of EBV lytic cycle in Akata and Mutu-I cells
in the presence of Bafilomycin A1 or after silencing Beclin1
expression markedly increased the EBV lytic antigens
expression, intracellular EBV DNA copies and viral particles
release. Recently, siRNA suppression of ATG5 or Beclin1 in
EBV-producing cells was shown to reduce EBV lytic gene
expression.31 These results are contrary to our findings.
Possible explanations for this discrepancy might be found in
the different strategy applied in order to silence the autophagy
genes (siRNA versus shRNA), the time frame of the
experiments or cell type specificity. Our data also indicate
that Rapamycin, the main activator of autophagy, only slightly
reduced EBV lytic genes expression and replication in Akata
and Mutu-I cells, suggesting that the virus-mediated inhibition
of autophagy is independent of mTOR signaling and occurs in
the late steps of the process. Immunofluorescence studies
revealed that Raji cells exposed to EBV lytic cycle activators
and Bafilomycin A1 almost doubled the percentage of cells in
which EBV was activated. At present, we do not knowwhether
the increment of EBV lytic genes expression and replication
detected in Bafilomycin A1-treated cells occurs at the single-
cell level or depends on a higher number of cells carrying the
activated virus. Possibly, both conditions arise at the same
time. In fact, inhibition of autophagy might prolong the activity
of EBV trans-activators, thereby enhancing EBV lytic gene
transcription as we have shown here, and/or increase the
Figure 6 Inhibition of autophagy by Beclin1 knockdown enhances EBV replication. (a) EBV-positive Akata cells transfected with shRNAs targeting Beclin1 (BECN1 shRNA)
or with scrambled shRNAs were incubated with IgG, and collected at the indicated times. The silencing efficiency of BECN1 shRNA and expression levels of EBV lytic protein
BZLF1, BRLF1 and BALF5 were analyzed by immunoblotting. One of three independent experiments is shown. (b) Cells were treated with IgG for 24 and 48 h. Both intracellular
and extracellular EBV DNA copies were detected by real-time PCR as described in the Materials and Methods section. The data representing the mean± S.D. of three
independent experiments are expressed as fold increment relative to time 0. *Po0.05, **Po0.01 and ***Po0.001
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number of cells in which the virus is able to complete the lytic
gene cascade.
Granato et al.31 reported that the autophagic activation is
instrumental for the early phases of EBV replication, but that in
the late steps, the virus blocks autophagy to prevent lysosomal
degradation. More recently, Nowag et al.32 showed that
autophagic membranes are stabilized by lytic EBV replication
and found LC3-II in the envelope of the viral particles, these
results suggesting EBV recruitment of autophagosomal
membranes during productive infection. We show that upon
activation of EBV lytic cycle, exposure of Akata and Mutu-I
cells to Bafilomicin A1 leads to increase in the LC3-II
component in the first 8 and 4 h, respectively. Because a
prolonged exposure of the cells to the drug mainly impairs
autophagosomes–lysosomes fusion,33 it is conceivable that
the increment of EBV lytic genes expression and replication
observed at later times is related to accumulation/stabilization
of the autophagic vesicles. In this respect, our data are in
agreement with the above reported findings as Bafilomycin A1
treatment would enhance EBV particles production by
boosting a mechanism the virus seems to adopt to exploit
the cellular autophagic pathway.
In summary, using cellular models in which EBV–host cell
interactions are likely to resemble those occurring in vivo upon
the virus switch from the latent to the productive cycle, we
found that autophagy is stimulated in the early phases of EBV
lytic reactivation, while it is suppressed later on. We propose
that EBV reactivation transiently stimulates autophagy, but
that early in the productive cycle of infection, the virus is able to
counteract this host defense pathway. The viral products and
the molecular mechanisms that allow EBV to suppress
autophagy remain to be elucidated. Because Beclin1 silencing
increases EBV gene expression and replication, stimulation of
autophagy appears to represent the cellular response to the
synthesis of the viral products rather than being activated by
the virus to favor the early phases of lytic infection.
We report here for the first time that inhibition of autophagy at
an early or at a late step of the process highly upregulated EBV
gene expression and replication and increased virion yield.
Efficient induction of EBV lytic program in EBV-related
malignancies by reagents such as 5 Aza or HDAC inhibitors
has been proposed as a kind of oncolytic therapy to kill the
latently infected tumor cells, especially in combination with
antiviral drugs.34 Several clinical trials designed to block
autophagy by hydroxychloroquine in multiple cancers are
currently carried on.35 We envisage that our findings might
have clinical relevance, as targeting autophagy with pharma-
cological inhibitors might be beneficial to maximize the
efficacy of an oncolytic viral therapy devised for the treatment
of EBV-related cancers.
Materials and Methods
Cell lines, EBV lytic cycle induction and reagents. EBV-positive
Akata, Mutu-I, Raji and EBV-negative Akata36 are BL-derived cell lines. Cells were
cultured in RPMI-1640 medium containing 10% fetal calf serum (FCS; Biological
Industries) and antibiotics in a 5% CO2 atmosphere and maintained at a density of
3.5 × 105/ml. To induce EBV lytic cycle, Akata and Mutu-I cells were diluted to 106/ml
in RPMI-1640 medium 10% FCS and treated with 10 μg/ml of goat anti-human IgG
(Sigma, St Louis, MO, USA) or 5 ng/ml of TGFβ1 (BD Pharmingen), respectively. To
activate the virus in Raji cells, the culture at a density of 5 × 105 cells/ml in RPMI
1640/2,5% FCS was exposed to 0,04 ng/ml TGF-β2 (Genzyme), 2 mM sodium
butyrate and 20 ng/ml P(BU)2 (Sigma-Aldrich, Milan, Italy). The efficiency of EBV
lytic cycle induction was evaluated in all cell lines by counting EA-positive cells after
immunofluorescence staining.
Rapamycin and Bafilomycin A1 were purchased from Sigma-Aldrich and were
used at a concentration of 5 and 2 nM, respectively.
To evaluate the autophagic flux, cells were incubated with EBV lytic cycle activators
in the absence or in the presence of 10 nM Bafilomycin A1 that was added, for each
time point, 2 h before collecting the cells. U0126 was purchased from Calbiochem
(Milan, Italy).
Immunoblotting. Equal amounts of proteins (20 μg), as determined by Bio-Rad
Protein Assay (Bio-Rad, Hercules, CA, USA), were resolved on a 8% or on a 12%
SDS-PAGE and electrotransferred to Amersham Hybond PVDF membrane (GE
Healthcare, Milan, Italy). Membranes were then blocked for 1 h at 25 °C in PBS
containing 5% nonfat dry milk and 0.1% Tween-20 (Sigma-Aldrich), and were
incubated for 1 h at 25 °C or overnight at 4 °C, with the following primary antibodies:
BRLF1 and BZLF1(1 : 200 and 1 : 100, respectively, both obtained from Argene
Biosoft, Verniolle, France), BALF5 (1 : 100), LC3 (1 : 8000, L7543) and β-actin
(1 : 5000) were purchased from Sigma, Beclin1(1 : 500; sc-10086) and ATG5 (1 : 200,
sc-133158) purchased from Santa Cruz (DBA, Milan, Italy), and phospho-p70 S6
kinase (1 : 1000, 07-018-I Millipore, Merk Spa, Vimodrone, MI, Italy). Phospho
ERK1/2 and ERK1/2 antibodies (1 : 500) were obtained from Cell Signaling
(EuroClone, Milan, Italy). The membranes were then incubated with the appropriate
secondary antibodies conjugated to HRP (1 : 7500, Bio-Rad). The specific signals,
visualized by Amersham ECL Plus kit (GE Healthcare) were quantified by
densitometric analysis by ImageJ free-share software (http://imagej.nih.gov/ij).
Fluorescence microscopy. Raji cells were incubated with EBV lytic cycle-
inducing agents in the absence or in the presence of Bafilomycin A1 on glass
coverslips in a 12-well plate. After 24 h, cells were washed with PBS and fixed with
methanol/acetone (1 : 1) for 5 min at − 20 °C. Fixed cells were incubated with LC3
antibodies for 1 h at 37 °C, rinsed with PBS and then incubated with anti-rabbit
TRITC-conjugated secondary antibodies (Bio-Rad) for 30 min at room temperature.
Next, cells were rinsed and incubated for 1 h at 37 °C with FITC-conjugated EBV EA
antibodies. After extensive wash, the glass coverslips were mounted onto the slides
with 0.1% (w/v) p-phenylenediamine in 10% (v/v) PBS, 90% (v/v) glycerol, pH 8,
and the specimens observed by using a Leica DM4000 fluorescence microscope
equipped with an FX 340 digital camera (Leica Microsystems, Milan, Italy).
Total RNA extraction and real-time RT-PCR. Total RNA extracted from
5 × 106 by using Trizol reagent (Life Technologies Italia, Monza MB, Italy) according to
the manufacturer’s instruction was treated with DNase I (Invitrogen, VWR
International, Milan, Italy) for 30 min at 37 °C. DNase was then inactivated by adding
EDTA to a final concentration of 5 mM, followed by 10 min heat inactivation at 65 °C.
An amount of 1 μg of RNA was reverse transcribed using Super Script III
(Life Technologies Italia) and oligo dT. cDNA was then analyzed by real-time PCR
using a SYBR green PCR Master Mix (Applied Biosystems, Waltham, MA, USA) on
an Applied Biosystems 7900HT Fast Real-Time PCR System based on the
manufacturer's specified parameters. Relative RT-PCR was determined using ΔΔCT
methods relative to control samples and to the stably expressed housekeeping gene
GAPDH. The primer sequences used to measure the transcription of EBV lytic genes
BALF5, BHLF1, BMRF1, BZLF1 and BRLF1 are listed in Supplementary Table 1.
Quantification of viral DNA. Intracellular viral DNA was extracted using a
Wizard genomic DNA purification kit (Promega, Milan, Italy) and treated with RNase
A for 30 min at 37 °C. The viral DNA was subjected to real-time PCR using SYBR
Green PCR Master Mix (Applied Biosystems) on an Applied Biosystems 7900HT
Fast Real-Time PCR System according to the manufacturer’s specified parameters.
Relative amounts were obtained as above described.
Viral DNA in the supernatant was extracted as described.37 Briefly, virus-
containing media were treated with 5 U/50 μl of DNaseI (New England Biolabs) for 1 h
at 37 °C. After DNaseI heat inactivation (10 min at 70 °C), supernatants were mixed
(1 : 1) with lysis buffer (0.1 mg of proteinase K/ml in water) and incubated for 60 min at
50 °C. After a further treatment at 75 °C for 20 min, the released viral DNA was
measured by real-time PCR analysis, using a standard curve derived from a serial
dilutions of Namalwa cell lysate, which contain two copies of integrated EBV genome
per Namalwa cell. Intracellular and extracellular EBV DNA was detected using
specific primers for the OriLyt region: 5′-CGTCTTACTGCCCAGCCTACTC-3′
(OriLyt-fwd), 5′-AGTGGGAGGGCAGGAAATG-3′ (OriLyt-rev).
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Lentivirus generation and Akata cells infection. Lentiviral particles
were produced by transfecting Hek293T cells with 10 μg of the lentiviral shRNA
vectors pLKO Scramble (Addgene, Cambridge, MA, USA) or pLKO Beclin1
(TRCN0000033550, Sigma-Aldrich), together with the packaging vectors pMD2.G
(2.5 μg, Addgene) and psPAX2 (7.5 μg, Addgene). Forty-eight hours later, the
supernatants containing the lentiviral particles were collected, supplemented with
polybrene (4 μg/ml) and FCS (10%), filtered (PES 0.45 μM filters, Corning) to remove
cell debris and incubated with Akata cells for 8 h. Mutu-I cells were infected with
lentivirus by mixing cells with the culture supernatant in the presence of 8 μg/ml
polybrene and then centrifuging the mixture at 450 × g for 90 min. Infected cells were
analyzed starting from 48 h after infection. Stable cell lines expressing siRNAs were
selected by supplementing the culture medium with 1 or 2.5 μg/ml puromycin for
Akata or Muti-I cells, respectively.
Statistical analysis. All data were analyzed using GraphPad Prism6
(GraphPad Software, Inc., La Jolla, CA, USA). The data, expressed as the
mean±S.D., were analyzed by two-way ANOVAs to determine statistical
differences. A P-value of o0.05 was considered statistically significant.
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